April 12, 2019

Tipapkinogen Sovacivec (TS) vaccine trial discussed in Lancet and CME

Leading the trial, Dr. Diane Harper spoke to The Lancet. "This is the first time that we have seen such a high level of HPV and grade 2–3 CIN clearance with a therapeutic vaccine.”

A promising new trial that effectively eliminated precancerous HPV types was subject of national and international focus this week. The trial on an experimental immunotherapy Tipapkinogen Sovacivec (TS) was led by Diane Harper, M.D., M.P.H., M.S., professor, and was the focus of an article in The Lancet and a MedPage Oncology/Hematology CME. The TS vaccine effectively eliminated the most severe cervical precancerous lesions without need for surgery. Harper is hopeful. “For women hoping to preserve their cervix, even a 24% clearance of both HPV and abnormal cells is promising, especially since surgery does not clear the causative agent,” she said to the Lancet. 

Read more about the trial, published this month in Gynecologic Oncology